Central role for aldose reductase pathway in myocardial ischemic injury

Aldose reductase (AR), a member of the aldo‐keto reductase family, has been implicated in the development of vascular and neurological complications of diabetes. Recently, we demonstrated that aldose reductase is a component of myocardial ischemic injury and that inhibitors of this enzyme protect rat hearts from ischemia‐reperfusion injury. To rigorously test the effect of aldose reductase on myocardial ischemia‐reperfusion injury, we used transgenic mice broadly overexpressing human aldose reductase (ARTg) driven by the major histocompatibility complex I promoter. Hearts from these ARTg or littermate mice (WT) (n=6 in each group) were isolated, perfused under normoxic conditions, then subjected to 50 min of severe low flow ischemia followed by 60 min of reperfusion. Creatine kinase (CK) release (a marker of ischemic injury) was measured during reperfusion; left ventricular developed pressure (LVDP), end diastolic pressure (EDP), and ATP were measured throughout the protocol. CK release was significantly greater in ARTg mice compared with the WT mice. LVDP recovery was significantly reduced in ARTg mice compared with the WT mice. Furthermore, ATP content was higher in WT mice compared with ARTg mice during ischemia and reperfusion. Infarct size measured by staining techniques and myocardial damage evaluated histologically were also significantly worse in ARTg mice hearts than in controls. Pharmacological inhibition of aldose reductase significantly reduced ischemic injury and improved functional recovery in ARTg mice. These data strongly support key roles for AR in ischemic injury and impairment of functional and metabolic recovery after ischemia. We propose that interventions targeting AR may provide a novel adjunctive approach to protect ischemic myocardium.—Hwang, Y. C., Kaneko, M., Bakr, S., Liao, H., Lu, Y., Lewis, E. R., Yan, S., Ii, S., Itakura, M., Rui, L., Skopicki, H., Homma, S., Schmidt, A. M., Oates, P. J., Szabolcs, M., Ramasamy, R. Central role for aldose reductase pathway in myocardial ischemic injury. FASEB J. 18, 1192–1199 (2004)

[1]  J. Ulbrecht,et al.  Glucose-induced Alterations in Nerve Metabolism: Current Perspective on the Pathogenesis of Diabetic Neuropathy and Future Directions for Research and Therapy , 1985, Diabetes Care.

[2]  E. Feldman,et al.  Aldose reductase inhibitors: an approach to the treatment of diabetic nerve damage. , 1993, Diabetes/metabolism reviews.

[3]  R. Larkins,et al.  Effect of inhibition of aldose reductase on glucose flux, diacylglycerol formation, protein kinase C, and phospholipase A2 activation. , 1997, Metabolism: clinical and experimental.

[4]  S. Srivastava,et al.  Activation of human erythrocyte, brain, aorta, muscle, and ocular tissue aldose reductase. , 1986, Metabolism: clinical and experimental.

[5]  T. Jomori,et al.  Sorbitol dehydrogenase overexpression potentiates glucose toxicity to cultured retinal pericytes. , 2002, Biochemical and biophysical research communications.

[6]  J. Mccormack,et al.  Regulation of myocardial carbohydrate metabolism under normal and ischaemic conditions Potential for pharmacological interventions , 1997 .

[7]  G. Lopaschuk,et al.  Beneficial Effect of Carnitine on Mechanical Recovery of Rat Hearts Reperfused After a Transient Period of Global Ischemia Is Accompanied by a Stimulation of Glucose Oxidation , 1993, Circulation.

[8]  J. Fujimoto,et al.  Acute onset of diabetic pathological changes in transgenic mice with human aldose reductase cDNA , 1995, Diabetologia.

[9]  J. Busik,et al.  Glucose-specific regulation of aldose reductase in capan-1 human pancreatic duct cells In vitro. , 1997, The Journal of clinical investigation.

[10]  P. Oates,et al.  Aldose reductase inhibition alone or combined with an adenosine A(3) agonist reduces ischemic myocardial injury. , 2000, American journal of physiology. Heart and circulatory physiology.

[11]  R. Ramasamy,et al.  Attenuation of ischemia induced increases in sodium and calcium by the aldose reductase inhibitor zopolrestat. , 1999, Cardiovascular research.

[12]  J. Park,et al.  Metabolic modulation of cellular redox potential can improve cardiac recovery from ischemia-reperfusion injury. , 1998, International journal of cardiology.

[13]  S. Srivastava,et al.  Metabolism of the Lipid Peroxidation Product, 4-Hydroxy-trans-2-nonenal, in Isolated Perfused Rat Heart* , 1998, The Journal of Biological Chemistry.

[14]  R. Ramasamy,et al.  Aldose reductase inhibition improves altered glucose metabolism of isolated diabetic rat hearts. , 1998, American journal of physiology. Heart and circulatory physiology.

[15]  G. Petsko,et al.  An anion binding site in human aldose reductase: mechanistic implications for the binding of citrate, cacodylate, and glucose 6-phosphate. , 1994, Biochemistry.

[16]  R. Ramasamy,et al.  Niacin protects the isolated heart from ischemia-reperfusion injury. , 2000, American journal of physiology. Heart and circulatory physiology.

[17]  S. Watowich,et al.  Structural and kinetic determinants of aldehyde reduction by aldose reductase. , 1999, Biochemistry.

[18]  C. Nishimura,et al.  The involvement of aldose reductase in diabetic complications. , 1988, Diabetes/metabolism reviews.

[19]  R. Ramasamy,et al.  Aldose reductase activation is a key component of myocardial response to ischemia , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[20]  C. Yabe-Nishimura,et al.  Clinical analysis of aldose reductase for differential diagnosis of the pathogenesis of diabetic complication , 1998 .

[21]  J. Williamson,et al.  An enzymatic fluorometric assay for fructose. , 2000, Analytical biochemistry.

[22]  P. Kador.  The role of aldose reductase in the development of diabetic complications , 1988, Medicinal research reviews.

[23]  S. Homma,et al.  Neovascularization of ischemic myocardium by human bone-marrow–derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function , 2001, Nature Medicine.

[24]  D. Greene,et al.  An aldose reductase inhibitor reverses early diabetes‐induced changes in peripheral nerve function, metabolism, and antioxidative defense , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[25]  J. Nyengaard,et al.  Hyperglycemic Pseudohypoxia and Diabetic Complications , 1993, Diabetes.

[26]  R. Ramasamy,et al.  Metabolic effects of aldose reductase inhibition during low-flow ischemia and reperfusion. , 1998, American journal of physiology. Heart and circulatory physiology.

[27]  R. Ramasamy,et al.  Sorbitol dehydrogenase: a novel target for adjunctive protection of ischemic myocardium , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[28]  R. Ramasamy,et al.  Aldose Reductase Inhibition Protects Diabetic and Nondiabetic Rat Hearts from Ischemic Injury , 1997, Diabetes.

[29]  T. Akera,et al.  Cloning and expression of human aldose reductase. , 1990, The Journal of biological chemistry.

[30]  N. Ansari,et al.  Cardiac metabolism of enals. , 1999, Advances in experimental medicine and biology.

[31]  Sookja K. Chung,et al.  Contribution of polyol pathway to diabetes-induced oxidative stress. , 2003, Journal of the American Society of Nephrology : JASN.

[32]  K. Gabbay.  The sorbitol pathway and the complications of diabetes. , 1973, The New England journal of medicine.

[33]  H. Taegtmeyer,et al.  Energy substrate metabolism, myocardial ischemia, and targets for pharmacotherapy. , 1998, The American journal of cardiology.

[34]  D. Greene,et al.  Sorbitol, phosphoinositides, and sodium-potassium-ATPase in the pathogenesis of diabetic complications. , 1987, The New England journal of medicine.

[35]  J. Kinoshita,et al.  Role of aldose reductase in the development of diabetes-associated complications. , 1985, The American journal of medicine.

[36]  R. Ramasamy,et al.  Glycogen utilization and ischemic injury in the isolated rat heart. , 1997, Cardiovascular research.